Get the Stockscreener App
4.73
3.05%
0.14
Rxsight Inc stock is traded at $4.73, with a volume of 978.77K.
It is up +3.05% in the last 24 hours and down -21.17% over the past month.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
See More
Previous Close:
$4.59
Open:
$4.64
24h Volume:
978.77K
Relative Volume:
1.23
Market Cap:
$195.81M
Revenue:
$134.48M
Net Income/Loss:
$-38.94M
P/E Ratio:
-4.9612
EPS:
-0.9534
Net Cash Flow:
$-19.34M
1W Performance:
-1.46%
1M Performance:
-21.17%
6M Performance:
-61.58%
1Y Performance:
-65.90%
1-Day Range:
$4.59
$4.73
1-Week Range:
$4.56
$4.94
52-Week Range:
$4.48
$14.29
Rxsight Inc Stock (RXST) Company Profile
Name
Rxsight Inc
Sector
Industry
Phone
949-521-7822
Address
100 COLUMBIA STREET, ALISO VIEJO
Compare RXST vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
4.73 | 195.81M | 134.48M | -38.94M | -19.34M | -0.9534 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Initiated | William Blair | Mkt Perform |
| Jul-15-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-10-25 | Downgrade | Jefferies | Buy → Hold |
| Jul-09-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-09-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-09-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-19-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-15-25 | Initiated | Piper Sandler | Neutral |
| Apr-09-25 | Downgrade | UBS | Buy → Neutral |
| Apr-04-25 | Downgrade | JP Morgan | Overweight → Underweight |
| Apr-03-25 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-20-24 | Downgrade | Stifel | Buy → Hold |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-06-24 | Initiated | UBS | Buy |
| Oct-29-24 | Initiated | Jefferies | Buy |
| Aug-20-24 | Reiterated | Needham | Buy |
| Aug-06-24 | Reiterated | Needham | Buy |
| May-07-24 | Reiterated | BTIG Research | Buy |
| Dec-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-23 | Initiated | Stifel | Buy |
| Dec-04-23 | Initiated | Morgan Stanley | Overweight |
| Apr-13-23 | Initiated | Oppenheimer | Outperform |
| Dec-12-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-08-22 | Initiated | Needham | Buy |
View All
Rxsight Inc Stock (RXST) Latest News
Rxsight Inc (RXST) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RxSight (RXST) director receives 37,037 restricted stock units in equity grant - Stock Titan
RxSight (RXST) director awarded 37,037 RSUs in equity compensation grant - Stock Titan
RxSight (RXST) director Shweta Maniar receives 37,037 RSU award - Stock Titan
Tamara Fountain at RxSight (RXST) receives 37,037-share RSU award - Stock Titan
RxSight (RXST) director William J. Link granted 37,037-share stock award - Stock Titan
RxSight (RXST) director Corley Jesse Anderson granted 37,037 RSUs - Stock Titan
RxSight (RXST) director granted 30,864 RSUs vesting by next meeting - Stock Titan
RxSight (RXST) director receives 37,037 RSUs, now directly holds 85,183 shares - Stock Titan
RxSight (RXST) director receives 37,037 RSUs vesting by next stockholder meeting - Stock Titan
Rxsight Inc (RXST) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rxsight Inc (RXST) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rxsight Inc (RXST) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rxsight Inc (RXST) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rxsight Inc (RXST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rxsight Inc (RXST) Institutional Confidence - TradingKey
Rxsight Inc (RXST) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
RxSight (RXST) investors re-elect board, approve pay and ratify Ernst & Young - Stock Titan
RxSight Inc Stock (US78419L1008): Valuation Focus After Strong Run In Eye Technology - AD HOC NEWS
Rxsight Inc (RXST) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RxSight, Inc. Hits 52-Week Low of $4.58 Amidst 92.2% Decline - MarketsMojo
RxSight, Inc. Stock Plummets to New 52-Week Low of $4.49 - MarketsMojo
RxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue Estimates - MSN
RxSight Inc. (RXST) Falters Near Support: Testing Key Levels After 1.96% DeclineDark Pool Sentiment - newsline.com
Understanding Momentum Shifts in (RXST) - Stock Traders Daily
RxSight, Inc. Hits 52-Week Low at $5.31 Amid Ongoing Struggles - MarketsMojo
RxSight, Inc. Hits 52-Week Low at USD 4.93 Amidst Ongoing Struggles - MarketsMojo
RxSight Inc. (RXST) Slides 3% as Stock Struggles Below Key Resistance at $5.03Put Wall - newsline.com
RxSight Inc. (RXST) Q1 2026 Earnings: EPS Miss Weighs on Shares Amid Operating ChallengesProfitability Analysis - newsline.com
RXST Technical Analysis & Stock Price Forecast - Intellectia AI
RxSight Inc stock (US78419L1008): Nasdaq-listed eye-care specialist in focus after recent price weak - AD HOC NEWS
RXST Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin; Stock DeclinesEarnings Call Highlights - newsline.com
RxSight Inc. (RXST) Slips 4.65% as Stock Challenges $5.06 Support LevelTICK Divergence - The Legal Advocate
RxSight Securities Lawsuit Advances After Court Denies Dismissal Bid - TipRanks
RXST Q1 2026 Earnings: EPS Misses Estimates Amid Ongoing Ramp-UpEPS Growth Rate - The Legal Advocate
Midday Stock Roundup: TTM Drops on Investor Day - Orange County Business Journal
RxSight Must Litigate Investor Suit Over Eye Lens System Demand - Bloomberg Law News
RXST: Premium IOL penetration grows as competitive headwinds ease and commercial focus intensifies - TradingView
Avoiding Lag: Real-Time Signals in (RXST) Movement - Stock Traders Daily
RxSight Inc. Q1 2026 Earnings: EPS Misses Estimates Amid Operational HeadwindsOne-Time Loss Impact - Newser
RxSight Q1 2026 Earnings: EPS Misses Estimates by 32% as Operational Costs WeighEarnings Beat Streak - The Legal Advocate
RxSight stock gains ahead of Stifel meeting, investors wait for signs of turnaround - Bez Kabli
RxSight to present at Stifel 2026 Virtual Ophthalmology Forum on May 26 - Pluang
RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum - The Manila Times
RxSight management to appear at Stifel 2026 virtual eye forum May 26 - Stock Titan
RxSight stock (US78419L1008): Q1 revenue dip and share slide put growth story to the test - AD HOC NEWS
Tarsus, RxSight Fall Despite Growth Signals - Orange County Business Journal
RxSight stock (US78419L1008): FDA-linked growth and execution stay in focus - AD HOC NEWS
RxSight stock (US78419L1008): FDA-backed growth story stays in focus - AD HOC NEWS
Number of shareholders of RxSight, Inc. – NASDAQ:RXST - TradingView
Discipline and Rules-Based Execution in RXST Response - Stock Traders Daily
Rxsight Inc Stock (RXST) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):